Understanding Drug Sensitivity and Tackling Resistance in Cancer. Read more about Understanding Drug Sensitivity and Tackling Resistance in Cancer.
Abstract P3-03-07: Single-institution retrospective analysis of lymph node (LN) change on breast MRI in patients with high risk early-stage breast cancer receiving neoadjuvant chemotherapy with and without immunotherapy on the ISPY-2 TRIAL. Read more about Abstract P3-03-07: Single-institution retrospective analysis of lymph node (LN) change on breast MRI in patients with high risk early-stage breast cancer receiving neoadjuvant chemotherapy with and without immunotherapy on the ISPY-2 TRIAL.
Abstract P3-02-02: FES-dedicated breast PET uptake in early-stage ER+ breast cancers. Read more about Abstract P3-02-02: FES-dedicated breast PET uptake in early-stage ER+ breast cancers.
Abstract P3-02-01: Initial experience of FES-dedicated breast PET imaging of early-stage ER+ invasive lobular carcinoma. Read more about Abstract P3-02-01: Initial experience of FES-dedicated breast PET imaging of early-stage ER+ invasive lobular carcinoma.
Abstract P2-02-02: Differences in levels of circulating tumor cells (CTC) and disseminated tumor cells (DTC) in early-stage lobular versus ductal breast cancer. Read more about Abstract P2-02-02: Differences in levels of circulating tumor cells (CTC) and disseminated tumor cells (DTC) in early-stage lobular versus ductal breast cancer.
Abstract OT1-10-02: I-SPY2 endocrine optimization protocol (EOP): A pilot neoadjuvant endocrine therapy study with amcenestrant as monotherapy or in combination with abemacicilib or letrozole in molecularly selected HR+/HER2- clinical stage 2/3 breast can Read more about Abstract OT1-10-02: I-SPY2 endocrine optimization protocol (EOP): A pilot neoadjuvant endocrine therapy study with amcenestrant as monotherapy or in combination with abemacicilib or letrozole in molecularly selected HR+/HER2- clinical stage 2/3 breast can
Abstract P5-19-04: The WISDOM study: Reducing sequential steps and implementing parallel workflows in pragmatic trials. Read more about Abstract P5-19-04: The WISDOM study: Reducing sequential steps and implementing parallel workflows in pragmatic trials.
Abstract P5-19-01: The impact of streamlined processes and patient-directed messaging to improve enrollment in a remote, pragmatic clinical trial. Read more about Abstract P5-19-01: The impact of streamlined processes and patient-directed messaging to improve enrollment in a remote, pragmatic clinical trial.
Abstract PD9-04: Tumor-released circulating orphan non-coding RNAs reflect treatment response and survival in breast cancer. Read more about Abstract PD9-04: Tumor-released circulating orphan non-coding RNAs reflect treatment response and survival in breast cancer.
Abstract PD15-08: Window of opportunity trial of neoadjuvant olaparib and durvalumab for triple negative or low ER-positive breast cancer. Read more about Abstract PD15-08: Window of opportunity trial of neoadjuvant olaparib and durvalumab for triple negative or low ER-positive breast cancer.
